Prostatic Hyperplasia: Clinical Trials

61 trials for Prostatic Hyperplasia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

61 completed. 61 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 461Completed 61

Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder.
Pyridostigmine oral tablet, Placebo - Underactive Bladder, TURP(transurethral Resection of Prostate)
Phase 4CompletedMenoufia University662024-04-012025-03-26
Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients With Prostate Volumes ≤ 40 ml: A Prospective Comparative Study
Tamsulosin 0.4 mg, Tadalafil 5mg, Tamsulosin and Tadalafil - BPH With Other Lower Urinary Tract Symptoms
Phase 4CompletedFayoum University Hospital952023-04-202025-02-05
The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH
Silodosin, Tamsolusin - BPH (Benign Prostatic Hyperplasia)
Phase 4CompletedShanghai Huilun Pharmaceutical Co., Ltd.1102022-07-182025-08-21
Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain
Self-Administered Nitrous Oxide, Oxygen - Prostate Disease, Malignancy
Phase 4CompletedBeth Israel Deaconess Medical Center1432021-12-122024-01-30
Deprescribing Tamsulosin in Older Men
Tamsulosin, Placebo - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Phase 4CompletedUniversity of California, San Francisco312021-09-182025-08-22
Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
Tranexamic acid - Kidney Calculi, Urologic Diseases
Phase 4CompletedNorthwestern University1102021-09-172026-10-15
Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome
1% Atropine drops, Epinephrine - Intraoperative Floppy Iris Syndrome, Cataract
Phase 4CompletedUniversity Hospital Olomouc1642020-07-012024-02-20
Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)
Silodosin, Tamsulosin - Benign Prostatic Hyperplasia
Phase 4CompletedBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh1412017-08-312019-09-27
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Mirabegron, Placebo, Tamsulosin Hydrochloride - Benign Prostatic Hyperplasia, Overactive Bladder
Phase 4CompletedAstellas Pharma Global Development, Inc.7152016-06-132024-11-12
Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool, International Prostate Symptom Score (IPSS) screening tool - Prostatic Hyperplasia
Phase 4CompletedGlaxoSmithKline16792016-05-122021-01-05
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
Mirabegron, Placebo, Tamsulosin - Overactive Bladder
Phase 4CompletedAstellas Pharma Inc5682016-01-252024-11-12
Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms
Tadalafil, Placebo - Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Phase 4CompletedUniversity of Florence862015-12-012021-04-28
The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil
Alfuzosin Hydrochloride 10 MG, Tamsulosin Hydrochloride 0.4 MG - Benign Prostatic Hyperplasia, Pupil Anomaly
Phase 4CompletedKocatepe University632015-10-292017-05-09
Benign Prostatic Hyperplasia and Ischemic Heart DIsease
Tamsulosin Oral Capsule, TURP - Ischaemic Heart Disease (IHD), Benign Prostatic Hyperplasia (BPH)
Phase 4CompletedI.M. Sechenov First Moscow State Medical University832015-09-012019-02-27
A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
Tadalafil, Placebo, Alpha1 Blocker - Benign Prostatic Hyperplasia
Phase 4CompletedEli Lilly and Company1712015-04-012017-07-02
A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy
ciprofloxacin, ciprofloxacin and gentamycine, culture based chemoprophylaxis - Benign Prostate Hyperplasia
Phase 4CompletedMansoura University5102015-04-012017-04-04
GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
Greenlight laser PVP, Bipolar TUVP - Benign Prostatic Hyperplasia
Phase 4CompletedMansoura University1202014-09-012019-06-12
PERmixon® in LUTS Evaluation Study (PERLES)
Permixon® 160 mg, Tamsulosine LP, Placebo matching Permixon® 160 mg - Benign Prostatic Hyperplasia (BPH)
Phase 4CompletedPierre Fabre Medicament8332014-04-012016-09-02
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
Silodosin, Laboratory tests, 3-days voiding diary - Nocturia, Benign Prostatic Hyperplasia
Phase 4CompletedJW Pharmaceutical1352014-01-022017-03-10
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration
Ertapenem - Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection
Phase 4CompletedAssistance Publique - Hôpitaux de Paris202013-12-012025-09-08

Showing 20 of 61. Sign in to see all of them.

Narrower conditions

Lower Urinary Tract Symptoms (14)  ·  Urinary Bladder, Overactive (6)  ·  Hypogonadism (2)  ·  Nocturia (2)  ·  Prostatic Neoplasms (2)  ·  Anxiety Disorders (1)  ·  Cataract (1)  ·  Choroid Diseases (1)  ·  Coronary Artery Disease (1)  ·  Ejaculatory Dysfunction (1)  ·  Erectile Dysfunction (1)  ·  Hyperplasia (1)  ·  Kidney Calculi (1)  ·  Kidney Diseases (1)

Broader conditions

Genital Diseases (61)  ·  Genital Diseases, Male (61)  ·  Male Urogenital Diseases (61)  ·  Urogenital Diseases (61)  ·  Prostatic Diseases (60)  ·  Pathological Conditions, Signs and Symptoms (25)  ·  Signs and Symptoms (23)  ·  Urological Manifestations (21)  ·  Female Urogenital Diseases (9)  ·  Female Urogenital Diseases and Pregnancy Complications (9)  ·  Urologic Diseases (8)  ·  Lower Urinary Tract Symptoms (7)  ·  Urinary Bladder Diseases (7)  ·  Endocrine System Diseases (2)  ·  Eye Diseases (2)

Interventions

Tamsulosin (16)  ·  Dutasteride (7)  ·  alfuzosin (7)  ·  silodosin (6)  ·  Tadalafil (4)  ·  Solifenacin Succinate (3)  ·  mirabegron (2)  ·  saw palmetto extract (2)  ·  5-alpha Reductase Inhibitors (1)  ·  Adrenergic alpha-1 Receptor Antagonists (1)  ·  Atracurium (1)  ·  Ciprofloxacin (1)  ·  Clinical Laboratory Techniques (1)  ·  Combined Modality Therapy (1)  ·  Doxazosin (1)

Sponsors

GlaxoSmithKline (5)  ·  Astellas Pharma Inc (4)  ·  Boehringer Ingelheim (4)  ·  Samsung Medical Center (4)  ·  Sanofi (4)  ·  JW Pharmaceutical (3)  ·  Mansoura University (2)  ·  Pierre Fabre Medicament (2)  ·  Siami, Paul F., M.D. (2)  ·  University of Florence (2)  ·  American Medical Systems (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Astellas Pharma Korea, Inc. (1)  ·  Astellas Pharma Taiwan, Inc. (1)

Countries

United States (11)  ·  South Korea (10)  ·  Italy (8)  ·  France (7)  ·  Spain (6)  ·  Egypt (5)  ·  Germany (5)  ·  Netherlands (4)  ·  Canada (3)  ·  Czechia (3)  ·  Japan (3)  ·  Taiwan (3)  ·  Greece (2)  ·  Hungary (2)  ·  United Kingdom (2)

Top investigators

Kyu-Sung Lee, Ph.D (4)  ·  Ahmed M Elshal, MD (2)  ·  Paul F Siami, MD (2)  ·  Albert Dahan, MD {hD (1)  ·  Alexis Te, MD (1)  ·  Alvin M Matsumoto, MD (1)  ·  Andrey Z Vinarov, PhD (1)  ·  Benedict Blayney, MD (1)  ·  Benjmain N Breyer, MD, MAS (1)  ·  Christopher R Chapple, MD (1)  ·  Claus G Roehrborn, MD (1)

Results publications

PMID 16465187, PMID 19394149, PMID 19732305, PMID 21251673, PMID 21575967, PMID 21738005, PMID 22010203, PMID 23452344, PMID 25261801, PMID 25613154, PMID 26544316, PMID 27324263, PMID 29044968, PMID 29394114, PMID 31148056, PMID 31961963, PMID 32558340, PMID 33245533, PMID 36222618, PMID 37160401, PMID 40977319, PMID 42406401

NIH funding

2014 (1), 2015 (1), K12DK111028 (1)